During the past decade, ÜBAG MVZ Dr. Vehling-Kaiser GmbH conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

Out of the total clinical trials conducted in "ÜBAG MVZ Dr. Vehling-Kaiser GmbH" #1 sponsor was "Christian Buske" with 3 trials, followed by "German CLL Study Group" with 2 trials sponsored, "Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest" with 2 trials sponsored, "Prof. Dr. M. Dreyling (co-chairman)" with 1 trials sponsored and "University Hospital Muenster" with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "ÜBAG MVZ Dr. Vehling-Kaiser GmbH" #1 collaborator was "Roche Pharma AG" with 3 trials as a collaborator, "Optimapharm" with 2 trials as a collaborator, "University of Ulm" with 2 trials as a collaborator, "X-act Cologne Clinical Research GmbH" with 2 trials as a collaborator and "Zentrum für Klinische Studien Ulm" with 2 trials as a collaborator. Other collaborators include 4 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "ÜBAG MVZ Dr. Vehling-Kaiser GmbH" are "Cholangiocarcinoma" (2 trials), "Gallbladder Cancer" (2 trials), "Hepatocellular Cancer" (2 trials), "Marginal Zone Lymphoma" (2 trials) and "Oesophageal Cancer" (2 trials). Many other conditions were trialed in "ÜBAG MVZ Dr. Vehling-Kaiser GmbH" in a lesser frequency.

Most popular intervention types in "ÜBAG MVZ Dr. Vehling-Kaiser GmbH" are "Drug" (6 trials), "Biological" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Copanlisib" (2 trials), "Rituximab" (2 trials), "Acalabrutinib" (1 trials), "Bortezomib" (1 trials) and "Carfilzomib + Ibrutinib" (1 trials). Other intervention names were less common.

The vast majority of trials in "ÜBAG MVZ Dr. Vehling-Kaiser GmbH" are 10 trials for "All" genders.

Currently, there are NaN active trials in "ÜBAG MVZ Dr. Vehling-Kaiser GmbH". undefined are not yet recruiting, 7 are recruiting, 2 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in ÜBAG MVZ Dr. Vehling-Kaiser GmbH, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in ÜBAG MVZ Dr. Vehling-Kaiser GmbH, 0 "Phase 1" clinical trials were conducted, 6 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".